Plasma AR and abiraterone-resistant prostate cancer

Alessandro Romanel, Delila Gasi Tandefelt, Vincenza Conteduca, Anuradha Jayaram, Nicola Casiraghi, Daniel Wetterskog, Samanta Salvi, Dino Amadori, Zafeiris Zafeiriou, Pasquale Rescigno, Diletta Bianchini, Giorgia Gurioli, Valentina Casadio, Suzanne Carreira, Jane Goodall, Anna Wingate, Roberta Ferraldeschi, Nina Tunariu, Penny Flohr, Ugo De GiorgiJohann S. De Bono, Francesca Demichelis, Gerhardt Attard

Research output: Contribution to journalArticle

Abstract

Androgen receptor (AR) gene aberrations are rare in prostate cancer before primary hormone treatment but emerge with castration resistance. To determine AR gene status using a minimally invasive assay that could have broad clinical utility, we developed a targeted next-generation sequencing approach amenable to plasma DNA, covering all AR coding bases and genomic regions that are highly informative in prostate cancer. We sequenced 274 plasma samples from 97 castration-resistant prostate cancer patients treated with abiraterone at two institutions. We controlled for normal DNA in patients' circulation and detected a sufficiently high tumor DNA fraction to quantify AR copy number state in 217 samples (80 patients). Detection of AR copy number gain and point mutations in plasma were inversely correlated, supported further by the enrichment of nonsynonymous versus synonymous mutations in AR copy number normal as opposed to AR gain samples. Whereas AR copy number was unchanged from before treatment to progression and no mutant AR alleles showed signal for acquired gain, we observed emergence of T878A or L702H AR amino acid changes in 13% of tumors at progression on abiraterone. Patients with AR gain or T878A or L702H before abiraterone (45%) were 4.9 and 7.8 times less likely to have a ≥50 or ≥90% decline in prostate-specific antigen (PSA), respectively, and had a significantly worse overall [hazard ratio (HR), 7.33; 95% confidence interval (CI), 3.51 to 15.34; P = 1.3 × 10-9) and progression-free (HR, 3.73; 95% CI, 2.17 to 6.41; P = 5.6 × 10-7) survival. Evaluation of plasma AR by next-generation sequencing could identify cancers with primary resistance to abiraterone.

Original languageEnglish
Article number312re10
JournalScience Translational Medicine
Volume7
Issue number312
DOIs
Publication statusPublished - Nov 4 2015

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Plasma AR and abiraterone-resistant prostate cancer'. Together they form a unique fingerprint.

  • Cite this

    Romanel, A., Tandefelt, D. G., Conteduca, V., Jayaram, A., Casiraghi, N., Wetterskog, D., Salvi, S., Amadori, D., Zafeiriou, Z., Rescigno, P., Bianchini, D., Gurioli, G., Casadio, V., Carreira, S., Goodall, J., Wingate, A., Ferraldeschi, R., Tunariu, N., Flohr, P., ... Attard, G. (2015). Plasma AR and abiraterone-resistant prostate cancer. Science Translational Medicine, 7(312), [312re10]. https://doi.org/10.1126/scitranslmed.aac9511